Sars-COV-2 infection leads to neurodegenerative or neuropsychiatric diseases
Keywords:
COVID-19, neurodegenerative diseases, viral RNA, neuropsychiatric disordersAbstract
The current COVID-19 epidemic caused by the new SARS-CoV-2 has severely harmed global healthcare (severe acute respiratory syndrome coronavirus). COVID-19's pulmonary and cardiovascular effects have been known from its inception, but its causes, mechanisms, and neuropath logical consequences remain unknown. Our research focused on neurological problems in COVID-19 patients, as well as probable SARS-CoV-2 infection routes like hematogenous, direct/neuronal, lymphatic tissue, cerebrospinal fluid, or infiltration by infected immune cells. Late December 2019 in Wuhan, China, a mysterious viral pneumonia struck. The disease was caused by a new corona virus. Corona virus infection spread rapidly from person to person in 2019. The WHO has called it a global public health emergency (WHO). Activation of NF-B in SARS-CoV-2 infection may be linked to immune cell pathogenicity, cytokine storms, and multi-organ failure. COVID-19's inhibition of the NF-B signaling pathway shows promising therapeutically. Inhibiting IKK phosphorylation, a critical downstream consequence of the NF-B signaling cascade, reduces COVID-19 levels. All three disorders have been linked to COVID-19 gene mutations. This study provides a biological basis for future research on COVID-19-related neurological disease. W
Downloads
References
Gilmore TD,et al. Herscovitch M Inhibitors of NF- κ B signaling: 785 and counting. Oncogene, 2002 ;25 (3) 6887–6899.
Wouk, J., Rechenchoski, D.Z., Rodrigues, B.C.D. et al. Viral infections and their relationship to neurological disorders. Arch Virol, 2021; (3)166 733-753 .
Goldstein DR Aging, imbalanced inflammation and viral infec tion. Virulence 2009; 295-298.
wogbindin IO, Ben-Azu B, Olusola BA, et al. Microglial Implications in SARS-CoV-2 Infection and COVID-19: Lessons From Viral RNA Neurotropism and Possible Relevance to Parkinson's Disease. Frontiers in Cellular Neuroscience, 2020; 2(1) 480-512
De Chiara G, Marcocci ME, Sgarbanti R et al. Infectious agents and neurodegeneration. Mol Neurobiol 2012;46(3) 614–638.
Grothe K, Flechsenhar K, Paehler T, Ritzeler O, Beninga J, Saas J, Herrmann M, Rudolphi K, IκB kinase inhibition as a potential treatment of osteoarthritis – results of a clinical proof-of-concept study. Osteoarthr Cartil 2017;25(2) 46–52.
Guan W, Liang W, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen PY, Sang L, et.al. China Medical Treatment Expert Group for COVID-19 Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020; (5) 20-47.
Hirano T, Murakami M COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity 2020;52(1)731-733.
Huang I, Pranata R Lymphopenia in severe coronavirus disease- 2019 (COVID-19): systematic review and meta-analysis. J Intensive Care2020; 8(6) .
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; (4)497-506.
Chou, S. H. Y., Beghi, E., Helbok, R., Moro, E., Sampson, J., Altamirano, V & ENERGY Consortium. Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19—A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium. JAMA network open, 2020;4(5) e2112131-e21121300.
Chen L, Deng H, Cui H et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget,2017; 9(7)204– 7218.
Franke, C., Ferse, C., Kreye, J., Reincke, S. M., Sanchez-Sendin, E., Rocco, A., ... & Prüß, H High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain, behavior, and immunity, 2021;93(5) 415-419.
Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G COVID-19: pathogen- esis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev 202;5(3) 66-70.
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y. & Cao, B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 2021;395(10223) 497-506.
Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré Syndrome Associated with SARS-CoV-2. N Engl J Med. 2020; 382(26) 74-76.
Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2021;4422(20) 2-4.
Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S, et al. Miller Fisher Syndrome and polyneuritis cranialis in COVID-19. Neurology2020;5(4) 65-70.
Pan Zhai, Yanbing Ding, Yiming Li et al. The impact of COVID-19 on ischemic stroke: A case report, 31 March , PREPRINT available at Research Square 2020.
Shi, L., Lu, Z. A., Que, J. Y., Huang, X. L., Liu, L., Ran, M. S., ... & Lu, L. Prevalence of and risk factors associated with mental health symptoms among the general population in China during the coronavirus disease 2019 pandemic. JAMA network open, 2020;3(7) 2014053-2014053.
Herman C, Mayer K, Sarwal A. Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19. Neurology, 2020;95(2) 77-84.
The Lancet Neurology. The neurological impact of COVID-19. Lancet Neurol. 2020;19(6):471-475.
Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol, 2020;19(9)767-783.
Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol,2021; 77(6) 683-690 .
Pleasure SJ, Green AJ, Josephson SA. The spectrum of neurologic disease in the severe acute respiratory syndrome coronavirus 2 pandemic infection: neurologists move to the frontlines. JAMA Neurol, 2020;(6)679-680.
Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med.2020; 382(23)2268-2270.
Beyrouti R, Adams ME, Benjamin L, et al. Characteristics of ischaemic stroke associated with COVID-19. J Neurol Neurosurg Psychiatry, 2020; 91(8)889-891.
Romero Cantero V, Moreno Pulido S, Duque Holguera M, Casado Naranjo I. COVID-19 and concomitant neurological infections. Article in Spanish. Neurologia, 2021;35(5) 332-333.
Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med.2020; 382(26) 2574-2576
Xiong W, Mu J, Guo J, et al. New onset neurologic events in people with COVID-19 in 3 regions in China. Neurology, 2020;95(11) 1479-1487.
Zanin L, Saraceno G, Panciani PP, et al. SARS-CoV-2 can induce brain and spine demyelinating lesions. Acta Neurochir (Wien), 2020;162(7)1491-1494.
Josephson SA, Kamel H. Neurology and COVID-19. JAMA 2020; 324(12)1139-1140.
Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol, 2020;77(8) 1018-1027 .
Merkler AE, Parikh NS, Mir S, et al. Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza. JAMA Neurol, (2020).
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020;395(10223) 507-513.
Majidi S, Fifi JT, Ladner TR, et al. Emergent large vessel occlusion stroke during New York City’s COVID-19 outbreak: clinical characteristics and paraclinical findings. Stroke, 2020; 51(9) 2656-2663.
Oxley TJ, Mocco J, Majidi S, et al. Large-vessel stroke as a presenting feature of COVID-19 in the young.Matschke J, Lütgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol, 2020;19 (11) 919-929 .
Li Y, Li M, Wang M, et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol,2020; 5 (3) 279-284 .
Liotta EM, Batra A, Clark JR, et al. Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. Ann Clin Transl Neurol, 2020;7(11) 2221-2230.
Varatharaj A, Thomas N, Ellul MA, et al; CoroNerve Study Group. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry.2020;7(10) 875-882 .
Benussi A, Pilotto A, Premi E, et al. Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy. Neurology, 2020;95(7) 910-920 .
Frontera JA, Sabadia S, Lalchan R, et al. A prospective study of neurologic disorders in hospitalized COVID-19 patients in New York City. Neurology.2020;96(4) 575-586.
Beghi E, Helbok R, Crean M, et al; EAN Neuro-COVID Task Force. The European Academy of Neurology COVID-19 registry (ENERGY): an international instrument for surveillance of neurological complications in patients with COVID-19. Eur J Neurol. 2020
Helbok R, Chou SH, Beghi E, et al; GCS-NeuroCOVID consortium; EAN COVID task force. NeuroCOVID: it’s time to join forces globally. Lancet Neurol,2020; 19(10) 805-806.
Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci. 2020;4(13)11-32.
Frontera J, Mainali S, Fink EL, et al; GCS-NeuroCOVID Study. Global Consortium Study of Neurological Dysfunction in COVID-19 (GCS-NeuroCOVID): study design and rationale. Neurocrit Care. 2020;33(1)25-34.
McNett M, Fink EL, Schober M, et al. The Global Consortium Study of Neurological Dysfunction in COVID-19 (GCS-NeuroCOVID): development of case report forms for global use. Neurocrit Care. 2020;33(3)793-828.
Moro E, Priori A, Beghi E, et al; EAN core COVID-19 Task Force. The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection. Eur J Neurol. 2020;27(9)1727-1737.
Shah VA, Nalleballe K, Zaghlouleh ME, Onteddu S. Acute encephalopathy is associated with worse outcomes in COVID-19 patients. Brain Behav Immun Health, 2020;25 (8) 100-136
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
